Endocrine and neuroendocrine tumours
- ESMO Preceptorship on Gastroenteropancreatic Neuroendocrine Neoplasms 2019: Prague
- eUpdate – Hepatocellular Carcinoma Treatment Recommendations
- FDA Approves Iobenguane I 131 for Pheochromocytoma or Paraganglioma
- EMA Recommends Extension of Indications for Lenvatinib
- FDA Approves Dabrafenib Plus Trametinib for Anaplastic Thyroid Cancer with BRAF V600E Mutation
- eUpdate – Medullary Thyroid Cancer Treatment Recommendations
- FDA Approves Lutetium Lu 177 Dotatate for Treatment of GEP NETs
- ESMO 2017: First KEYNOTE-028 Report of Pembrolizumab Activity in Patients with PD-L1-positive pNETs and Carcinoid Tumours
- ESMO 2017: Immune Landscape of PanNETs
- ESMO 2017: Improved Survival Demonstrated with NSCLC-chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma with RB1 Wild-type
- ESMO 2017: Subtypes of Thymic Carcinomas Show Different Genomic Alterations and Tumour Mutational Burden
- EMA Recommends Granting a Marketing Authorisation for Telotristat Ethyl
- EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide
- FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhoea
- Nature Reviews Clinical Oncology – Year in Review
- EMA Recommends Extension of Therapeutic Indications for Vandetanib
- ESMO 2016: Metformin Significantly Lowers the Risk of Cancer Progression in Patients with Diabetes and Advanced pNETs
- ESMO 2016: The NETwork! Translational Programme Facilitates Genomic Analysis of Neuroendocrine Tumours
- ESMO 2016: Clinical Benefit Demonstrated with Everolimus and Pasireotide LAR Alone or in Combination in the First Randomised, Prospective Study Entirely Dedicated to Advanced Lung and Thymic Carcinoids
- EMA Recommends Granting a Marketing Authorisation for Edotreotide
- FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumours
- Everolimus for the Treatment of Advanced, Non-Functional Neuroendocrine Tumours of the Lung or Gastrointestinal Tract (RADIANT-4): a Randomised, Placebo-Controlled, Phase 3 Study
- EMA Recommends Granting a Marketing Authorisation for Lutetium (177 Lu) Chloride
- EMA Adopts a New Indication for Everolimus
- Dabrafenib Produces Rapid Shrinkage of Recurrent, BRAF-mutant Papillary Craniopharyngioma